Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.

Kitatani K, Usui T, Sriraman SK, Toyoshima M, Ishibashi M, Shigeta S, Nagase S, Sakamoto M, Ogiso H, Okazaki T, Hannun YA, Torchilin VP, Yaegashi N.

Oncogene. 2016 May;35(21):2801-12. doi: 10.1038/onc.2015.330. Epub 2015 Sep 14.

2.
3.

Lysosomal degradation of CD44 mediates ceramide nanoliposome-induced anoikis and diminished extravasation in metastatic carcinoma cells.

Haakenson JK, Khokhlatchev AV, Choi YJ, Linton SS, Zhang P, Zaki PM, Fu C, Cooper TK, Manni A, Zhu J, Fox TE, Dong C, Kester M.

J Biol Chem. 2015 Mar 27;290(13):8632-43. doi: 10.1074/jbc.M114.609677. Epub 2015 Feb 13.

4.

Ceramide induced mitophagy and tumor suppression.

Dany M, Ogretmen B.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt B):2834-45. doi: 10.1016/j.bbamcr.2014.12.039. Epub 2015 Jan 26. Review.

PMID:
25634657
5.

Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel.

Feng LX, Li M, Liu YJ, Yang SM, Zhang N.

Int J Mol Sci. 2014 Mar 10;15(3):4201-20. doi: 10.3390/ijms15034201.

6.

The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.

Dhule SS, Penfornis P, He J, Harris MR, Terry T, John V, Pochampally R.

Mol Pharm. 2014 Feb 3;11(2):417-27. doi: 10.1021/mp400366r. Epub 2014 Jan 24.

7.

PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery.

Zou P, Stern ST, Sun D.

Pharm Res. 2014 Mar;31(3):684-93. doi: 10.1007/s11095-013-1190-5. Epub 2013 Sep 25.

8.

A review of ceramide analogs as potential anticancer agents.

Liu J, Beckman BS, Foroozesh M.

Future Med Chem. 2013 Aug;5(12):1405-21. doi: 10.4155/fmc.13.107. Review.

9.

Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models.

Adiseshaiah PP, Clogston JD, McLeland CB, Rodriguez J, Potter TM, Neun BW, Skoczen SL, Shanmugavelandy SS, Kester M, Stern ST, McNeil SE.

Cancer Lett. 2013 Sep 1;337(2):254-65. doi: 10.1016/j.canlet.2013.04.034. Epub 2013 May 7.

10.

Complexation of c6-ceramide with cholesteryl phosphocholine - a potent solvent-free ceramide delivery formulation for cells in culture.

Sukumaran P, Lönnfors M, Långvik O, Pulli I, Törnquist K, Slotte JP.

PLoS One. 2013 Apr 19;8(4):e61290. doi: 10.1371/journal.pone.0061290. Print 2013.

11.

pHLIP®-mediated delivery of PEGylated liposomes to cancer cells.

Yao L, Daniels J, Wijesinghe D, Andreev OA, Reshetnyak YK.

J Control Release. 2013 May 10;167(3):228-37. doi: 10.1016/j.jconrel.2013.01.037. Epub 2013 Feb 15.

12.

Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.

Morad SA, Madigan JP, Levin JC, Abdelmageed N, Karimi R, Rosenberg DW, Kester M, Shanmugavelandy SS, Cabot MC.

Biochem Pharmacol. 2013 Apr 15;85(8):1057-65. doi: 10.1016/j.bcp.2013.01.015. Epub 2013 Jan 24.

13.

Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.

Watters RJ, Fox TE, Tan SF, Shanmugavelandy S, Choby JE, Broeg K, Liao J, Kester M, Cabot MC, Loughran TP, Liu X.

Leuk Lymphoma. 2013 Jun;54(6):1288-96. doi: 10.3109/10428194.2012.752485. Epub 2012 Dec 31.

14.

Trojan-horse nanotube on-command intracellular drug delivery.

Wu CH, Cao C, Kim JH, Hsu CH, Wanebo HJ, Bowen WD, Xu J, Marshall J.

Nano Lett. 2012 Nov 14;12(11):5475-80. doi: 10.1021/nl301865c. Epub 2012 Oct 25.

15.

Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.

Bocci G, Fioravanti A, Orlandi P, Di Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G, Danesi R.

Neoplasia. 2012 Sep;14(9):833-45.

16.

Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.

Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC.

Mol Cancer Ther. 2012 Nov;11(11):2352-61. doi: 10.1158/1535-7163.MCT-12-0594. Epub 2012 Sep 7.

17.

Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.

Leblanc F, Zhang D, Liu X, Loughran TP.

Future Oncol. 2012 Jul;8(7):787-801. doi: 10.2217/fon.12.75. Review.

18.

Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.

Koshkaryev A, Piroyan A, Torchilin VP.

Cancer Biol Ther. 2012 Jan 1;13(1):50-60. doi: 10.4161/cbt.13.1.18871.

19.

Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.

Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M.

Cancer Biol Ther. 2011 Oct 1;12(7):574-85. Epub 2011 Oct 1.

20.

Transcriptional regulation of the human neutral ceramidase gene.

O'Neill SM, Yun JK, Fox TE, Kester M.

Arch Biochem Biophys. 2011 Jul;511(1-2):21-30. doi: 10.1016/j.abb.2011.04.012. Epub 2011 Apr 22.

Items per page

Supplemental Content

Write to the Help Desk